Semax
Human observationalCommunity-reported ranges are anecdotal and not clinically validated. Evidence grade shown reflects the strength of available human data. Not a prescription. Legal status varies by country and changes over time; verify locally.
Overview
An ACTH-derived peptide with decades of clinical use in Russia for stroke recovery, cognitive complaints and attention, and a popular intranasal nootropic elsewhere. The independent, Western RCT base hasn't caught up with that regional clinical history.
Mechanism
Modulates BDNF and neurotrophic signalling in the originating research, the proposed route to its cognitive and neuroprotective effects.
Evidence
Substantial regional clinical use and human studies from its country of origin; independent replication is limited.
Community-reported information
Community reports vary. Anecdotal and unvalidated; general information only.
General information only, not tailored to you and not a recommendation. Some regions withhold this entirely.
Half-life
Short (intranasal use common).
Storage
Refrigerate solutions.
Commonly reported side effects
- Not well characterised
- Nasal irritation (intranasal)
Legal status by region
- USNot FDA-approved; not a lawful supplement ingredient.
Legal status changes over time; verify locally before relying on this.
Frequently asked questions
- Is Semax approved anywhere?
- It is used in clinical settings in Russia, but it is not FDA-approved and robust independent RCT evidence is limited.
- How is Semax taken?
- It is commonly used intranasally. This is descriptive information, not a usage recommendation.
Citations
- Semax researchPubMed